Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus. Twenty patients entered a 3-month, double-blind, placebo-controlled st...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2000-04, Vol.101 (15), p.1773-1779 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1779 |
|---|---|
| container_issue | 15 |
| container_start_page | 1773 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 101 |
| creator | EVANS, M ANDERSON, R. A GRAHAM, J ELLIS, G. R MORRIS, K DAVIES, S JACKSON, S. K LEWIS, M. J FRENNEAUX, M. P REES, A |
| description | Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.
Twenty patients entered a 3-month, double-blind, placebo-controlled study. Each subject was studied fasting and after a fatty meal, at baseline, and after 3 months of treatment. Glucose and lipid profiles were measured over an 8-hour postprandial period. Endothelial function (flow-mediated endothelium-dependent vasodilatation [FMD]) and oxidative stress (electron paramagnetic resonance spectroscopy) were measured after fasting and 4 hours postprandially. At baseline, both groups exhibited similar PPL and deterioration in endothelial function. After ciprofibrate, fasting and postprandial FMD values were significantly higher (from 3.8+/-1. 8% and 1.8+/-1.3% to 4.8+/-1.1% and 3.4+/-1.1%; P |
| doi_str_mv | 10.1161/01.cir.101.15.1773 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_212674808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>53721069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-60ea6fc74013ce37ebba3d352cdc2dc2609ffafd9b889d256058c92dfbabcacc3</originalsourceid><addsrcrecordid>eNpNkF9rVDEQxYNY7Lb1C_ggQXy9aybZJPc-ylK1UBDEPofcZIIp959JbnHf-8HNugsVBoY5_M4Mcwh5B2wLoOATg62LaQu1g9yC1uIV2YDku2YnRfeabBhjXaMF55fkKufHOiqh5RtyCUyrjmu1Ic_7uKQ5xD7ZgrT8wmSXA41jFZ8wU5z8XMUh2oGGdXIlzhO1k6cJ_eoqsMy5LKkqR2KIC47R_gPmP9HbEp-Q5pIwZxonWg4LUk4r22Op5hGHIZY135CLYIeMb8_9mjx8uf25_9bcf_96t_983zgJrDSKoVXB6R0D4VBo7HsrvJDcecdrKdaFYIPv-rbtPJeKydZ13Ife9s46J67Jh9Pe-t3vFXMxj_OapnrScOBK71rWVoifIJfmnBMGs6Q42nQwwMwxd8PA7O9-1BEMSHPMvZrenzev_Yj-P8sp6Ap8PAM2OzuEGpmL-YUTQnWqFX8BVeyPqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212674808</pqid></control><display><type>article</type><title>Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>EVANS, M ; ANDERSON, R. A ; GRAHAM, J ; ELLIS, G. R ; MORRIS, K ; DAVIES, S ; JACKSON, S. K ; LEWIS, M. J ; FRENNEAUX, M. P ; REES, A</creator><creatorcontrib>EVANS, M ; ANDERSON, R. A ; GRAHAM, J ; ELLIS, G. R ; MORRIS, K ; DAVIES, S ; JACKSON, S. K ; LEWIS, M. J ; FRENNEAUX, M. P ; REES, A</creatorcontrib><description>Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.
Twenty patients entered a 3-month, double-blind, placebo-controlled study. Each subject was studied fasting and after a fatty meal, at baseline, and after 3 months of treatment. Glucose and lipid profiles were measured over an 8-hour postprandial period. Endothelial function (flow-mediated endothelium-dependent vasodilatation [FMD]) and oxidative stress (electron paramagnetic resonance spectroscopy) were measured after fasting and 4 hours postprandially. At baseline, both groups exhibited similar PPL and deterioration in endothelial function. After ciprofibrate, fasting and postprandial FMD values were significantly higher (from 3.8+/-1. 8% and 1.8+/-1.3% to 4.8+/-1.1% and 3.4+/-1.1%; P<0.05). This was mirrored by a fall in fasting and postprandial triglycerides (3. 1+/-2.1 and 6.6+/-4.1 mmol/L to 1.5+/-0.8 and 2.8+/-1.3 mmol/L, P<0. 05). Fasting and postprandial HDL cholesterol was also elevated (0. 9+/-0.1 and 0.8+/-0.1 mmol/L and 1.2+/-0.2 and 1.2+/-0.1 mmol/L, P<0. 05). There were no changes in total or LDL cholesterol. Fasting and postprandial triglyceride enrichment of all lipoproteins was attenuated, with cholesterol depletion of VLDL and enrichment of HDL. There were similar postprandial increases in oxidative stress in both groups at baseline, which was significantly attenuated by ciprofibrate (0.3+/-0.6 versus 1.5+/-1.1 U, P<0.05).
This study demonstrates that fibrate therapy improves fasting and postprandial endothelial function in type 2 diabetes. Attenuation of PPL and the associated oxidative stress, with increased HDL cholesterol levels, may be important.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.cir.101.15.1773</identifier><identifier>PMID: 10769276</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Analysis of Variance ; Area Under Curve ; Biological and medical sciences ; Cholesterol, HDL - blood ; Clofibric Acid - analogs & derivatives ; Clofibric Acid - therapeutic use ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - physiopathology ; Female ; Fibric Acids ; General and cellular metabolism. Vitamins ; Humans ; Hypolipidemic Agents - therapeutic use ; Lipids - blood ; Male ; Medical sciences ; Middle Aged ; Oxidative Stress ; Pharmacology. Drug treatments ; Postprandial Period ; Triglycerides - blood</subject><ispartof>Circulation (New York, N.Y.), 2000-04, Vol.101 (15), p.1773-1779</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Apr 18, 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-60ea6fc74013ce37ebba3d352cdc2dc2609ffafd9b889d256058c92dfbabcacc3</citedby><cites>FETCH-LOGICAL-c510t-60ea6fc74013ce37ebba3d352cdc2dc2609ffafd9b889d256058c92dfbabcacc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1336968$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10769276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>EVANS, M</creatorcontrib><creatorcontrib>ANDERSON, R. A</creatorcontrib><creatorcontrib>GRAHAM, J</creatorcontrib><creatorcontrib>ELLIS, G. R</creatorcontrib><creatorcontrib>MORRIS, K</creatorcontrib><creatorcontrib>DAVIES, S</creatorcontrib><creatorcontrib>JACKSON, S. K</creatorcontrib><creatorcontrib>LEWIS, M. J</creatorcontrib><creatorcontrib>FRENNEAUX, M. P</creatorcontrib><creatorcontrib>REES, A</creatorcontrib><title>Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.
Twenty patients entered a 3-month, double-blind, placebo-controlled study. Each subject was studied fasting and after a fatty meal, at baseline, and after 3 months of treatment. Glucose and lipid profiles were measured over an 8-hour postprandial period. Endothelial function (flow-mediated endothelium-dependent vasodilatation [FMD]) and oxidative stress (electron paramagnetic resonance spectroscopy) were measured after fasting and 4 hours postprandially. At baseline, both groups exhibited similar PPL and deterioration in endothelial function. After ciprofibrate, fasting and postprandial FMD values were significantly higher (from 3.8+/-1. 8% and 1.8+/-1.3% to 4.8+/-1.1% and 3.4+/-1.1%; P<0.05). This was mirrored by a fall in fasting and postprandial triglycerides (3. 1+/-2.1 and 6.6+/-4.1 mmol/L to 1.5+/-0.8 and 2.8+/-1.3 mmol/L, P<0. 05). Fasting and postprandial HDL cholesterol was also elevated (0. 9+/-0.1 and 0.8+/-0.1 mmol/L and 1.2+/-0.2 and 1.2+/-0.1 mmol/L, P<0. 05). There were no changes in total or LDL cholesterol. Fasting and postprandial triglyceride enrichment of all lipoproteins was attenuated, with cholesterol depletion of VLDL and enrichment of HDL. There were similar postprandial increases in oxidative stress in both groups at baseline, which was significantly attenuated by ciprofibrate (0.3+/-0.6 versus 1.5+/-1.1 U, P<0.05).
This study demonstrates that fibrate therapy improves fasting and postprandial endothelial function in type 2 diabetes. Attenuation of PPL and the associated oxidative stress, with increased HDL cholesterol levels, may be important.</description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cholesterol, HDL - blood</subject><subject>Clofibric Acid - analogs & derivatives</subject><subject>Clofibric Acid - therapeutic use</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Double-Blind Method</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Female</subject><subject>Fibric Acids</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Oxidative Stress</subject><subject>Pharmacology. Drug treatments</subject><subject>Postprandial Period</subject><subject>Triglycerides - blood</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkF9rVDEQxYNY7Lb1C_ggQXy9aybZJPc-ylK1UBDEPofcZIIp959JbnHf-8HNugsVBoY5_M4Mcwh5B2wLoOATg62LaQu1g9yC1uIV2YDku2YnRfeabBhjXaMF55fkKufHOiqh5RtyCUyrjmu1Ic_7uKQ5xD7ZgrT8wmSXA41jFZ8wU5z8XMUh2oGGdXIlzhO1k6cJ_eoqsMy5LKkqR2KIC47R_gPmP9HbEp-Q5pIwZxonWg4LUk4r22Op5hGHIZY135CLYIeMb8_9mjx8uf25_9bcf_96t_983zgJrDSKoVXB6R0D4VBo7HsrvJDcecdrKdaFYIPv-rbtPJeKydZ13Ife9s46J67Jh9Pe-t3vFXMxj_OapnrScOBK71rWVoifIJfmnBMGs6Q42nQwwMwxd8PA7O9-1BEMSHPMvZrenzev_Yj-P8sp6Ap8PAM2OzuEGpmL-YUTQnWqFX8BVeyPqg</recordid><startdate>20000418</startdate><enddate>20000418</enddate><creator>EVANS, M</creator><creator>ANDERSON, R. A</creator><creator>GRAHAM, J</creator><creator>ELLIS, G. R</creator><creator>MORRIS, K</creator><creator>DAVIES, S</creator><creator>JACKSON, S. K</creator><creator>LEWIS, M. J</creator><creator>FRENNEAUX, M. P</creator><creator>REES, A</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope></search><sort><creationdate>20000418</creationdate><title>Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus</title><author>EVANS, M ; ANDERSON, R. A ; GRAHAM, J ; ELLIS, G. R ; MORRIS, K ; DAVIES, S ; JACKSON, S. K ; LEWIS, M. J ; FRENNEAUX, M. P ; REES, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-60ea6fc74013ce37ebba3d352cdc2dc2609ffafd9b889d256058c92dfbabcacc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cholesterol, HDL - blood</topic><topic>Clofibric Acid - analogs & derivatives</topic><topic>Clofibric Acid - therapeutic use</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Double-Blind Method</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Female</topic><topic>Fibric Acids</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Oxidative Stress</topic><topic>Pharmacology. Drug treatments</topic><topic>Postprandial Period</topic><topic>Triglycerides - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>EVANS, M</creatorcontrib><creatorcontrib>ANDERSON, R. A</creatorcontrib><creatorcontrib>GRAHAM, J</creatorcontrib><creatorcontrib>ELLIS, G. R</creatorcontrib><creatorcontrib>MORRIS, K</creatorcontrib><creatorcontrib>DAVIES, S</creatorcontrib><creatorcontrib>JACKSON, S. K</creatorcontrib><creatorcontrib>LEWIS, M. J</creatorcontrib><creatorcontrib>FRENNEAUX, M. P</creatorcontrib><creatorcontrib>REES, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>EVANS, M</au><au>ANDERSON, R. A</au><au>GRAHAM, J</au><au>ELLIS, G. R</au><au>MORRIS, K</au><au>DAVIES, S</au><au>JACKSON, S. K</au><au>LEWIS, M. J</au><au>FRENNEAUX, M. P</au><au>REES, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2000-04-18</date><risdate>2000</risdate><volume>101</volume><issue>15</issue><spage>1773</spage><epage>1779</epage><pages>1773-1779</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus.
Twenty patients entered a 3-month, double-blind, placebo-controlled study. Each subject was studied fasting and after a fatty meal, at baseline, and after 3 months of treatment. Glucose and lipid profiles were measured over an 8-hour postprandial period. Endothelial function (flow-mediated endothelium-dependent vasodilatation [FMD]) and oxidative stress (electron paramagnetic resonance spectroscopy) were measured after fasting and 4 hours postprandially. At baseline, both groups exhibited similar PPL and deterioration in endothelial function. After ciprofibrate, fasting and postprandial FMD values were significantly higher (from 3.8+/-1. 8% and 1.8+/-1.3% to 4.8+/-1.1% and 3.4+/-1.1%; P<0.05). This was mirrored by a fall in fasting and postprandial triglycerides (3. 1+/-2.1 and 6.6+/-4.1 mmol/L to 1.5+/-0.8 and 2.8+/-1.3 mmol/L, P<0. 05). Fasting and postprandial HDL cholesterol was also elevated (0. 9+/-0.1 and 0.8+/-0.1 mmol/L and 1.2+/-0.2 and 1.2+/-0.1 mmol/L, P<0. 05). There were no changes in total or LDL cholesterol. Fasting and postprandial triglyceride enrichment of all lipoproteins was attenuated, with cholesterol depletion of VLDL and enrichment of HDL. There were similar postprandial increases in oxidative stress in both groups at baseline, which was significantly attenuated by ciprofibrate (0.3+/-0.6 versus 1.5+/-1.1 U, P<0.05).
This study demonstrates that fibrate therapy improves fasting and postprandial endothelial function in type 2 diabetes. Attenuation of PPL and the associated oxidative stress, with increased HDL cholesterol levels, may be important.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>10769276</pmid><doi>10.1161/01.cir.101.15.1773</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 2000-04, Vol.101 (15), p.1773-1779 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_journals_212674808 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Adult Analysis of Variance Area Under Curve Biological and medical sciences Cholesterol, HDL - blood Clofibric Acid - analogs & derivatives Clofibric Acid - therapeutic use Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Endothelium, Vascular - drug effects Endothelium, Vascular - physiopathology Female Fibric Acids General and cellular metabolism. Vitamins Humans Hypolipidemic Agents - therapeutic use Lipids - blood Male Medical sciences Middle Aged Oxidative Stress Pharmacology. Drug treatments Postprandial Period Triglycerides - blood |
| title | Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T15%3A07%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ciprofibrate%20therapy%20improves%20endothelial%20function%20and%20reduces%20postprandial%20lipemia%20and%20oxidative%20stress%20in%20type%202%20diabetes%20mellitus&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=EVANS,%20M&rft.date=2000-04-18&rft.volume=101&rft.issue=15&rft.spage=1773&rft.epage=1779&rft.pages=1773-1779&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.cir.101.15.1773&rft_dat=%3Cproquest_cross%3E53721069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212674808&rft_id=info:pmid/10769276&rfr_iscdi=true |